Armephaco JSC

Armephaco JSC CapEx/D&A

The CapEx to Depreciation Ratio of Armephaco JSC (AMP.VN) as of Oct 31, 2026 is 4.23. In the previous year, CapEx to Depreciation Ratio was 4.15 — a change of 1.88% (higher).

CapEx/D&A

4.23

YoY

1.88%

Last updated:

CapEx to Depreciation Ratio of Armephaco JSC is 2024 4.23 . CapEx to Depreciation Ratio of Armephaco JSC was 2023 4.15 . It decreases by 1.88% higher compared to the previous year.

The Armephaco JSC CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
2.32 VND
Jan 1, 2018
0.89 VND
Jan 1, 2019
0.66 VND
Jan 1, 2020
4.23 VND
Jan 1, 2021
2.25 VND
Jan 1, 2022
0.63 VND
Jan 1, 2023
4.15 VND
Jan 1, 2024
4.23 VND
The Armephaco JSC CapEx/D&A history
YEARCapEx/D&AYoY
4.23+1.88%
4.15+557.77%
0.63-71.91%
2.25-46.87%
4.23+540.89%
0.66-26.01%
0.89-61.61%
2.32+34.23%
1.73-82.07%
9.65—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Armephaco JSC Stock analysis

What does Armephaco JSC do? Armephaco JSC manufactures pharmaceutical and medical equipment products, focusing on glucose meters, sphygmomanometers, beds, medical exam tables, stools, and syringe destroyers. The company distributes medical devices and equipment through its manufacturing and distribution channels, targeting healthcare providers and hospitals. It also produces and trades diversified medicines, including antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs, serving the broader healthcare market. The firm generates revenue from the sale of medical devices and equipment, as well as from pharmaceutical products. Healthcare providers and hospitals purchase the medical devices and equipment, while the diversified medicines are sold to pharmacies and healthcare institutions. Armephaco JSC's product portfolio includes glucose meters, sphygmomanometers, beds, medical exam tables, stools, syringe destroyers, antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs. Armephaco JSC's business model centers on the production and distribution of medical devices and pharmaceuticals. The company's primary customers are healthcare providers, hospitals, pharmacies, and healthcare institutions. The revenue streams are derived from the direct sale of medical equipment and pharmaceutical products to these segments, with no mention of additional services or partnerships. Armephaco JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Armephaco JSC stock

CapEx to Depreciation Ratio of Armephaco JSC is 4.23 in 2024.

CapEx to Depreciation Ratio of Armephaco JSC changed from 4.15 to 4.23, representing a 1.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Armephaco JSC since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Armephaco JSC with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Armephaco JSC

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Armephaco JSC